Eli Lilly & Co. Inc.’s stock rose 2.3% Wednesday, after the company said its Zepbound weight-loss drug was more effective ...

Shares of Amgen Inc. AMGN inched 0.08% higher to $278.32 Tuesday, on what proved to be an all-around mixed trading session ...

Patients with recurrent platinum-sensitive ovarian cancer did just as well with cytoreductive surgery alone as they did with ...

"Importantly, although the most commonly considered osteoporotic fractures (hip, vertebral, forearm, humerus, and pelvis) ...

Shares of Amgen (NASDAQ: AMGN) are down by 6% in the last 30 days as I write this -- a larger-than-normal amount for a large ...

The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...

Shares of Amgen (NASDAQ:AMGN) have recently been under pressure due to the increasing focus on the highly anticipated phase 2 readout of MariTide in obese and type 2 diabetes patients. Last week ...

As Amgen (NASDAQ:AMGN) shares are down 9% following the release of highly anticipated phase 2 data on its weight loss drug MariTide, Street analysts are weighing in. And there's a theme ...

Weight loss benefits from Amgen's monthly injection MariTide miss investor expectations MariTide's trial results comparable to Novo Nordisk and Eli Lilly drugs, with slightly more side effects ...

Amgen's experimental weight loss injection, MariTide, showed up to 20% weight loss in patients without diabetes and 17% in ...